Microablative Radiofrequency in the Treatment of Urinary Symptoms Associated With Genitourinary Syndrome of Menopause
Microablative Radiofrequency in the Treatment of Urinary Symptoms Associated With Genitourinary Syndrome of Menopause: Randomized Clinical Trial
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Patricia V Lordelo, Phd
- Phone Number: +5571996592400
- Email: pvslordelo@hotmail.com
Study Locations
-
-
Ba
-
Salvador, Ba, Brazil, 40.290-000
- Centro de Atenção ao Assoalho Pélvico
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Clinical complaint of urinary incontinence associated to Genitourinary Syndrome of Menopause.
- Negative cervical oncotic cytology, within the last 3 years.
Exclusion Criteria:
- Patients with cognitive deficit;
- Patients with chronic degenerative neurological diseases;
- Post-void residue greater than 50 ml;
- Carriers of a pacemaker and implantable cardioverter defibrillator;
- Use of hormonal therapy (topical or systemic) starting in the 2 months prior to the initial assessment;
- Patients undergoing brachytherapy or pelvic radiotherapy;
- Patients that had reconstructive pelvic surgery;
- Pregnant women.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Control Group
Pelvic floor muscle training
|
Verbal information will be given about location, function and the correct way to contract the pelvic floor muscles (PFM).
Participants will be instructed on how to perform "The Knack", which is a pre-contraction of the PFM during some abdominal effort, such as coughing, sneezing or laughing.
The exercises consist of two series of 10 maximum contractions sustained for 5 seconds and 10 seconds of relaxation and two series of 10 maximum rapid contractions with two seconds of maintenance and four seconds of relaxation, with one minute of rest between each series.
Participants will be instructed to perform the same exercises at home (twice a day) and to fill out a training diary, allowing researchers to monitor and check whether the exercises are actually being performed.
The protocol will be repeated with the researcher three times in total, every 30 to 40 days.
|
|
Experimental: Intervention Group
Pelvic floor muscle training and microablative radiofrequency
|
Verbal information will be given about location, function and the correct way to contract the pelvic floor muscles (PFM).
Participants will be instructed on how to perform "The Knack", which is a pre-contraction of the PFM during some abdominal effort, such as coughing, sneezing or laughing.
The exercises consist of two series of 10 maximum contractions sustained for 5 seconds and 10 seconds of relaxation and two series of 10 maximum rapid contractions with two seconds of maintenance and four seconds of relaxation, with one minute of rest between each series.
Participants will be instructed to perform the same exercises at home (twice a day) and to fill out a training diary, allowing researchers to monitor and check whether the exercises are actually being performed.
The protocol will be repeated with the researcher three times in total, every 30 to 40 days.
Patients will be placed in the lithotomy position and through speculum examination and under direct vision or guided by colposcope, sequential application of radiofrequency will be carried out on the vaginal walls and introitus.
The Wavetronic 6000 Touch device will be used with the Megapulse HF FRAXX system (Loktal Medical Electronics, São Paulo, Brazil), equipped with an electronic energy fractionation circuit, connected to a vaginal pen with 64 microneedles, 200μm in diameter and 1 mm in length, mounted on a Teflon body and divided into a matrix of eight columns with eight needles each.
In the vestibule and vaginal opening, 10% lidocaine spray will be applied three minutes before the procedure.
Three applications will be carried out in the vagina/vaginal introitus, with an interval of 30 to 40 days.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Resolution or improvement of episodes of urinary loss assessed by pad test
Time Frame: Before the beginning of the treatment, 30 days after the end of treatment and 12 months after the end of the treatment.
|
Participants will perform the one-hour Pad Test to diagnose and quantify urinary loss.
Initially, the absorbent will be placed in a closed plastic bag and weighed on a precision electronic scale (Denver Instrument®).
Then, the participant will be instructed to put on the pad, drink 500 ml of water in a maximum of 15 minutes and remain at rest for another 15 minutes, this phase represents 30 minutes of the test.
In the other 30 minutes, the participant will be asked to perform certain standardized activities simulating activities of daily life (going up and down stairs, sitting down and standing up ten times, coughing ten times, picking up objects from the floor five times, running in the same place for one minute and washing the hands under running water for one minute).
|
Before the beginning of the treatment, 30 days after the end of treatment and 12 months after the end of the treatment.
|
|
Resolution or improvement of episodes of urinary loss assessed by urinary diary
Time Frame: Before the beginning of the treatment, 30 days after the end of treatment and 12 months after the end of the treatment
|
Participants will be instructed to keep a voiding diary at home for three days to record water intake, urinary volume and the number of incontinence episodes, as well as episodes of urgency and nocturnal enuresis.
|
Before the beginning of the treatment, 30 days after the end of treatment and 12 months after the end of the treatment
|
|
Number of patients with tolerability related to treatment assessed by Likert Scale.
Time Frame: At each of the three sessions (every 30 to 40 days), 30 days after the end of treatment and 12 months after the end of the treatment.
|
Likert scale of 3 points will be asked to the patients: 1) impossible to tolerate the treatment, 2) not nice, but possible to tolerate, 3) very tolerable.
|
At each of the three sessions (every 30 to 40 days), 30 days after the end of treatment and 12 months after the end of the treatment.
|
|
Number of patients with adverse effects related to treatment assessed by histopathology.
Time Frame: Before the beginning of the treatment, 30 days after the end of treatment and 12 months after the end of the treatment.
|
To evaluate the safety in tissue effect of FRAXX, samples of vaginal tissue will be obtained through a biopsy taken from the lateral walls, in the middle third of the vagina, for histopathological study.
Procedure carried out under colposcopic vision, using a 3mm loop attached to the radiofrequency device, "surgery" mode, removing a small vaginal fragment.
|
Before the beginning of the treatment, 30 days after the end of treatment and 12 months after the end of the treatment.
|
|
Resolution or improvement of episodes of urinary loss assessed by questionnaire.
Time Frame: Before the beginning of the treatment, 30 days after the end of treatment and 12 months after the end of the treatment.
|
The questionnaire to be used will be International Consultation on Incontinence Questionnaire- Short Form (ICIQ-SF) which is a self-administered questionnaire that assesses the impact of UI on quality of life and the classification of urinary loss.
The ICIQ-SF is composed of four questions that assess the frequency, severity and impact of UI, in addition to a set of eight self-diagnosis items, related to the causes or situations of UI experienced by patients.
The higher the score, the greater the severity of urinary incontinence and the greater the impact on the patient's quality of life.
|
Before the beginning of the treatment, 30 days after the end of treatment and 12 months after the end of the treatment.
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Recovery of vaginal health assessed by Vaginal Index Maturation
Time Frame: Before the beginning of the treatment, 30 days after the end of treatment and 12 months after the end of the treatment
|
The cytological evaluation will be carried out using a vaginal smear collected from the lateral vaginal wall with a spatula ; the percentage of superficial (%S), intermediate (%I) and parabasal (P%) cells are counted and the mucosa is then classified according to the Vaginal Maturation Index (VMI) of the Meisel formula [(1, 0 x %S) + (0.5 x %I) + (0.0 x %P)] as atrophic, hypotrophic or eutrophic.
|
Before the beginning of the treatment, 30 days after the end of treatment and 12 months after the end of the treatment
|
|
Recovery of vaginal health assessed by vaginal pH
Time Frame: Before the beginning of the treatment, 30 days after the end of treatment and 12 months after the end of the treatment
|
Vaginal pH will be measured with a pH indicator strip between 0 and 14 (MColorpHastTM, Merck, Germany), placed in contact with the mucosa of the middle third of the vaginal canal, with the help of a speculum.
|
Before the beginning of the treatment, 30 days after the end of treatment and 12 months after the end of the treatment
|
|
Improvement of Sexual Function assessed by Female Sexual Function Index
Time Frame: Before the beginning of the treatment, 30 days after the end of treatment and 12 months after the end of the treatment
|
A self-administered questionnaire, which proposes to evaluate female sexual response in the domains: sexual desire, sexual arousal, vaginal lubrication, orgasm, sexual satisfaction and pain.
It presents 19 questions that assess sexual function in the last four weeks and presents scores for each component.
For each question there is a response pattern, between 0 and 5 in an increasing order, except for questions about pain, where the score is reversed.
The domain that presents a score equal to zero means that the interviewee did not report sexual intercourse in the last four weeks.
Individual scores are obtained by summing the items that comprise each domain (simple score), which are multiplied by the factor of that domain and provide the weighted score.
The final score (total score: minimum of 2 and maximum of 36) is obtained by adding the weighted scores for each domain.
The cut-off is: > or = 26 points - no sexual dysfunction; bellow 26 - sexual dysfunction.
|
Before the beginning of the treatment, 30 days after the end of treatment and 12 months after the end of the treatment
|
|
Improvement of quality of life assessed by Short-Form Health Survey (SF-36)
Time Frame: Before the beginning of the treatment, 30 days after the end of treatment and 12 months after the end of the treatment
|
It consists of 36 items that encompass 8 domains: functional capacity, physical aspects, pain, general health, vitality, social aspects, emotional aspects and mental health.
It presents a final score from 0 to 100, where zero represents the worst general health status and 100 the best general health status.
|
Before the beginning of the treatment, 30 days after the end of treatment and 12 months after the end of the treatment
|
|
Improvement or resolution of urinary incontinence and the impact on quality of life assessed by King's Health Questionnaire.
Time Frame: Before the beginning of the treatment, 30 days after the end of treatment and 12 months after the end of the treatment
|
It consists of 21 questions and has four to five answer options on the LIKERT scale.
It involves nine domains: general health perceptions, impact of incontinence, function restrictions, physical limitations, social limitations, personal relationships, emotions, sleep and energy, and severity measures.
Furthermore, it has an independent scale called Symptom Severity Scale, which contains 11 items, measuring the presence and severity of urinary symptoms.
The score, both per domain and its global score, is obtained from a minimum of 0 (best quality of life) to a maximum of 100 (worst quality of life).
|
Before the beginning of the treatment, 30 days after the end of treatment and 12 months after the end of the treatment
|
|
Degree of patient satisfaction using a five-point Likert scale.
Time Frame: Before the beginning of the treatment, 30 days after the end of treatment and 12 months after the end of the treatment
|
It will classify patient's level of satisfaction as: 1) very dissatisfied; 2) dissatisfied; 3) unchanged; 4) satisfied; 5) very satisfied.
|
Before the beginning of the treatment, 30 days after the end of treatment and 12 months after the end of the treatment
|
|
Evolution of vaginal symptoms assessed by Visual Analogue Scale (VAS)
Time Frame: Immediately after the initial physical examination and at the end of each of the three session (every 30 to 40 days).
|
Intensity of vaginal symptoms (dryness, pain during sexual activity, vaginal laxity, itching, burning sensation and pain in the vaginal introitus) will be asked to the participants.
VAS is divided from 0 to 10 points.
0 will be considered as absence of the symptom and 10 will represent the maximum possible symptom.
|
Immediately after the initial physical examination and at the end of each of the three session (every 30 to 40 days).
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Patrícia Lordelo, PhD, Pelvic Floor Care Center
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 71168623.6.0000.5544
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.